Abstract
Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma patients on maintenance lenalidomide or bortezomib following autologous HCT. One hundred thirty-seven multiple myeloma patients on maintenance lenalidomide or bortezomib post-auto-HCT who received either MMR or herpes zoster vaccine were analyzed and any adverse events documented in the medical record in the 42 days following vaccination were recorded. Patients were vaccinated a median of 25 months (range, 18–62) post transplant. The most common post-vaccination adverse event was upper respiratory tract infection (18/137 patients); no rash attributed to vaccine strains or other adverse outcomes potentially related to the vaccines were identified. MMR and herpes zoster vaccination were safe and well-tolerated in this cohort.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia Open Access 19 August 2020
-
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Annals of Hematology Open Access 16 April 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ljungman P, Lewensohn-Fuchs I, Hammarström V, Aschan J, Brandt L, Bolme P, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657–63. http://www.bloodjournal.org/content/84/2/657.abstract.
Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267:1237–41.
Pauksen K, Duraj V, Ljungman P, Sjölin J, Oberg G, Lönnerholm G, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9:427–32. http://www.ncbi.nlm.nih.gov/pubmed/1628126.
Adell C, Bayas JM, Vilella A, Perales M, Vidal J, Bertran MJ, et al. Post-transplantation vaccination of bone-marrow transplant recipients. Med Clin. 2002;119:405–9.
Inazawa N, Hori T, Nojima M, Saito M, Igarashi K, Yamamoto M, et al. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017;89:358–62.
Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13:277–83. http://www.ncbi.nlm.nih.gov/pubmed/8199570.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. http://www.nejm.org/doi/abs/10.1056/NEJMoa051016.
Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers MED, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110:3071–7.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.
Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, et al. Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18:1426–34.
Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–16.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89. http://ascopubs.org/doi/10.1200/JCO.2017.72.6679.
Issa NC, Marty FM, Leblebjian H, Galar A, Shea MM, Antin JH, Soiffer RJ, Baden LR. Live-attenuated varicella zoster vaccine in hematopoietic stem-cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:285–7.
Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997;157:73–8.
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784–90.
Acknowledgements
This research was presented in part at IDWeek on October 25-30, 2016 in New Orleans, LA, as posters #2327 and #2328.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
PGR has received research funding from Takeda, BMS, and Celgene; serves on advisory boards for Takeda, Janssen, and Celgene. FMM has received research funding from Astellas, Chimerix, Merck, and Shire; and consulting honoraria from Alexion, Chimerix, LFB, Roche Molecular Diagnostics, and Shire. NCI has received research funding from Astellas and Merck and consulting honoraria from Akros Pharma. The remaining authors AP, HL, SPH, JPL, and LRB declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pandit, A., Leblebjian, H., Hammond, S.P. et al. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant 53, 942–945 (2018). https://doi.org/10.1038/s41409-018-0112-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0112-x
This article is cited by
-
Impfungen in der Hämatologie und Onkologie
best practice onkologie (2023)
-
Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis
World Journal of Pediatrics (2023)
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia (2021)
-
Impfen bei Immundefizienz
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2020)
-
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Annals of Hematology (2020)